Future Studies in Psychoneuroimmunology

  • T. Peter Bridge
  • Loring J. Ingraham


While the presence of a chapter on the future of psychoneuroimmunology in a book concerning the acquired immune deficiency syndrome (AIDS) suggests that the two areas are coextensive, they are not. Nonetheless, there is a great deal of overlap between the two areas. The progress that must be made in combatting AIDS needs to include the expertise of neuroscientists and immunologists knowledgeable in the interface of the immune system and central nervous system (CNS). Presented here then are a review of psychoneuroimmunology and suggestions for the future.


Human Immunodeficiency Virus Human Immunodeficiency Virus Infection Acquire Immune Deficiency Syndrome Natural Killer Cell Activity Human Immunodeficiency Virus Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gallo RC, Salahuddin SZ, Popovic M, et al: Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS. Science 224: 500–502, 1984.PubMedCrossRefGoogle Scholar
  2. 2.
    Weiss SH, Goedert JJ, Sarngadharan MG, et al: Screening test for HTLV-III antibodies. JAMA 253: 22 1225, 1985.Google Scholar
  3. 3.
    Levy JA, Hoffman AD, Kramer SM, et al: Isolation of lympocytotrophic retroviruses from San Francisco patients with AIDS. Science 225: 840–842, 1984.PubMedCrossRefGoogle Scholar
  4. 4.
    Fauci AS, Masur H, Gelmann EP, et al: The acquired immunodeficiency syndrome: An update. Ann Intern Med 102: 800–813, 1985.PubMedCrossRefGoogle Scholar
  5. 5.
    Centers for Disease Control: Revision of the case definition of acquired immunodeficiency syndrome for national reporting—United States. MMWR 34: 373–375, 1985.Google Scholar
  6. 6.
    Fauci AS, Macher AM, Longo, DL, et al: Acquired immunodeficiency syndrome. Ann Intern Med 100: 9 2106, 1984.Google Scholar
  7. 7.
    Darko DF: A brief tour of psychoneuroimmunology. Ann Allergy 57: 233–238, 1986.PubMedGoogle Scholar
  8. 8.
    Hoffman AD, Banapour B, Levy JA: Characterization of AIDS associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology 147: 326–335, 1985.PubMedCrossRefGoogle Scholar
  9. 9.
    Coffin JM: Genetic variation in AIDS viruses. Background paper. Washington, DC: Committee on National Strategy for AIDS, 1986.Google Scholar
  10. 10.
    Gartner S, Markovits P, Markovitz DM, et al: Virus isolation from and identification of HTLV-III/LAVproducing cells in brain tissue from a patient with AIDS. JAMA 256: 2365–2371, 1986.PubMedCrossRefGoogle Scholar
  11. 11.
    Dalgleish AG, Beverley PCL, Clapham PR, et al: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (Loud) 312: 763–767, 1984.CrossRefGoogle Scholar
  12. 12.
    Pert CB, Hill JM, Ruff MR, et al: Octapeptide deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T cell infectivity. Proc Natl Acad Sci USA 23: 9254–9258, 1986.CrossRefGoogle Scholar
  13. 13.
    Gartner S, Markovits P, Markovitz DM, et al: The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233: 215–219, 1986.PubMedCrossRefGoogle Scholar
  14. 14.
    Stoler MH, Eskin TA, Benn S, et al: HTLV-III Infection of the central nervous system. JAMA 256: 2360 2364, 1986.Google Scholar
  15. 15.
    Chiodi F, Asjo B, Fenyo EM, et al: Isolation of HIV from CSF of antibody positive virus carrier without neurological symptoms. Lancet 1:1276–1277, 1986.Google Scholar
  16. 16.
    Engel G: A unified concept of health and disease. Perspect Med Biol 3: 459–485, 1960.Google Scholar
  17. 17.
    Holmes TH, Treuting T, Wolff HG: Life situations emotions, and nasal disease. Psychosom Med 13: 71–82, 1951.PubMedGoogle Scholar
  18. 18.
    Carroll BJ: The hypothalamic pituitary adrenal axis: Functions, control mechanisms and methods of study, in Davies B, Carroll BJ, Mowbray RM (eds): Depressive Illness, Some Research Studies. Springfield, Illinois, Charles C Thomas, 1972, pp. 23–68.Google Scholar
  19. 19.
    Sachar AJ, Asnis G, Halbreich U, et al: Recent studies in the neuroendocrinology of major depressive disorders. Psychiatr Clin North Am 3: 313–326, 1980.Google Scholar
  20. 20.
    Targum SD, Sullivan AC, Byrnes SM: Neuroendocrine interrelationships in major depressive disorders. Am J Psychiatry 139: 282–286, 1982.PubMedGoogle Scholar
  21. 21.
    Blalock JE, McMenamin DH, Smith EM: Peptide hormones shared by the neuroendocrine and immunologic systems. J Immunol 135: 858s - 861s, 1985.PubMedGoogle Scholar
  22. 22.
    Blalock JE, Smith EM: Human leukocyte interferon. Proc Natl Acad Sci USA 77: 5972–5974, 1980.PubMedCrossRefGoogle Scholar
  23. 23.
    Smith EM, Phan M, Coppenhaver D, et al: Human leukocyte production of immunoreactive thyrotropin. Proc Nat Acad Sci USA 80: 6010–6011, 1983.PubMedCrossRefGoogle Scholar
  24. 24.
    Giachetti A, Goth A, Said SA: VIP in rabbit platelets and mast cells. Fed Proc 37: 357–361, 1978.Google Scholar
  25. 25.
    O’Dorisio MS, O’Dorisio TM, Cataland S, et al: VIP as a biochemical marker for polymorphonuclear leukocytes. J Lab Clin Med 96: 966–971, 1980.Google Scholar
  26. 26.
    Lygren I Revhaug A, Burhol PG, et al: VIP and somatostatin in leukocytes. Scand J Clin Lab Invest 44:347–349, 1984.Google Scholar
  27. 27.
    Smith EM, Morrill AC, Meyer WJ, et al: CRF induction of leukocyte derived immunoreactive ACTH and endorphins. Nature (Lond) 321: 881, 1986.CrossRefGoogle Scholar
  28. 28.
    Blalock JE: Relationships between neuroendocrine hormones and lymphokines. Lymphokines 9: 1–13, 1984.Google Scholar
  29. 29.
    Hall NR, McGillis JP, Spangelo BL, et al: Evidence that thymosins can function as neuroactive immunotransmitters. J Immunol 135: 806s - 811s, 1985.PubMedGoogle Scholar
  30. 30.
    Blalock JE, Harp C: Interferon and ACTH induction of steroidogenesis. Arch Virol 67: 45–49, 1981.PubMedCrossRefGoogle Scholar
  31. 31.
    Chany C, Rousset S, Bourgeade MF: Regulatory effects of interferons in various cells. Ann NY Acad Sci 350: 254–265, 1980.PubMedCrossRefGoogle Scholar
  32. 32.
    Smith EM, Blalock JE: Human lymphocyte production of CRF and endorphin. Proc Natl Acad Sci USA 78: 7530–7534, 1981.PubMedCrossRefGoogle Scholar
  33. 33.
    Friedman R. Interferon interaction with thyroid cells. J Interferon Res 2:387, 1982.Google Scholar
  34. 34.
    Blalock JE, Stanton J: Common pathways of interferon and hormonal action. Nature (Lond) 283: 406–408, 1980.CrossRefGoogle Scholar
  35. 35.
    Blalock JE, Smith EM: Human leukocyte interferon. Biochem Biophy Res Commun 101: 472–478, 1981.CrossRefGoogle Scholar
  36. 36.
    Kelso A, Munck A: Glucocorticoid inhibition of lymphokine secretion. J Immunol 133: 784–791, 1984.PubMedGoogle Scholar
  37. 37.
    Adams F, Quesada JR, Gutterman JU: Neuropsychiatrie manifestations of human leukocyte interferon therapy in patients with cancer. JAMA, 252: 938–941, 1984.PubMedCrossRefGoogle Scholar
  38. 38.
    Abrams PG, McClamrock E, Foon KA: Evening administration of alpha interferon. N Engl J Med 312: 443444, 1985.Google Scholar
  39. 39.
    Preble O, Torrey EF: Serum interferon in patients with psychosis. Am J Psychiatry 142: 1184–1186, 1985.PubMedGoogle Scholar
  40. 40.
    Roy A, Pickar D, Ninan P, et al: A search for interferon in CSF of schizophrenics. Am J Psychiatry 142: 269, 1985.Google Scholar
  41. 41.
    Rimon RH, Halonen P, Lebow P, et al: Antibrain antibodies and interferon in the serum and the cerebrospinal fluid of patients with schizophrenia, in Mozorov P (ed): Research on the Viral Hypothesis of Mental Disorders. Basel Karger, 1983, pp 161–167.Google Scholar
  42. 42.
    Besedovsky H, Del Rey A, Sorkin E, et al: Immunoregulatory feedback between interleukin I and glucocorticoid hormones. Science 233: 652–654, 1986.PubMedCrossRefGoogle Scholar
  43. 43.
    Krueger J, Walter J, Dinarello CA, et al: Sleep promoting effect of interleukin 1. Am J Physio1246: 994–999, 1984.Google Scholar
  44. 44.
    Rubinow DR, Joffe RT, Brouwers P, et al: Neuropsychiatric impairment in patients with AIDS. Adv Biochem Psychopharm 44: 111–115, (1988).Google Scholar
  45. 45.
    Moldofsky H, Lue FA, Eisen J, et al: The relationship of interleukin-1 and immune functions to sleep in humans. Psychosom Med 48: 309–318, 1986.PubMedGoogle Scholar
  46. 46.
    Krueger JM, Karnovsky ML: Sleep and the immune response. Ann NY Acad Sci 496: 510–516, 1987.PubMedCrossRefGoogle Scholar
  47. 47.
    Friedman H, Klein T, Specter S, et al: Drugs of abuse and virus susceptibility. Adv Biochem Psychopharm 44: 125–137, (1988).Google Scholar
  48. 48.
    Khansari N, Whitten HD, Fudenberg HH: Phencyclidine induced immunodepression. Science 225: 76–78, 1984.PubMedCrossRefGoogle Scholar
  49. 49.
    Jerrell TR, Maretta CA, Bone G, et al: Ethanol associated immunosuppression. Adv Biochem Psychopharm 44: 173–185, (1988).Google Scholar
  50. 50.
    Verma DS, Spitzer G, Gutterman JU, et al: Human leukocyte interferon-mediated granulopoietic differentiation arrest and its abrogation by lithium. Am J Hematol 12: 39–46, 1982.PubMedCrossRefGoogle Scholar
  51. 51.
    Fernandez LA, Fox RA: Perturbation of the immune system by lithium. Clin Exp Immunol 41: 527–532, 1980.PubMedGoogle Scholar
  52. 52.
    Libikowa H: Psychopharmaca and ECT in relation to interferon. Arch Immunol Ther Exp 25: 641–649, 1977.Google Scholar
  53. 53.
    Shaskan EG, Lovett EJ: Effects of haloperidol, a dopamine receptor antagonist, on a delayed type hypersensitivity reaction to 1-chloro, -2, 4-dinitrobenzene in mice. Res Common Psychiat. and Behay. 5: 241–254, (1980).Google Scholar
  54. 54.
    Roszman TL, Jackson JC, Cross RJ, et al: Neuroanatomic and neurotransmitter influences on immune function. J Immunol 135: 769s - 772s, 1985.PubMedGoogle Scholar
  55. 55.
    Stanisz AJ, Befus D, Bienenstock J: Differential effects of vasoactive intestinial peptide, substance P, and somatostatin on immunoglobin synthesis and proliferations by lymphocytes from Peyer’s patches, mesenteric lymph nodes, and spleen. J Immunol 136: 152–156, 1986.PubMedGoogle Scholar
  56. 56.
    Hall NR, Suria A, Goldstein AL: Lymphokine Res 4: 339–341, 1985.PubMedGoogle Scholar
  57. 57.
    Ader R, Cohen N: Behaviorally conditioned immunosuppression. Psychosom Med 37: 333–340, 1975.PubMedGoogle Scholar
  58. 58.
    Kiecolt-Glaser JK, Garner W, Speicher C, et al: Psychosocial modifiers of immunocompetence. Psychosom Med 46: 7–11, 1984.PubMedGoogle Scholar
  59. 59.
    Stein M, Keller SE, Schleifer SJ: Stress and immunomodulation: The role of depression and neuroendocrine function. J Immunol 135: 827s - 833s, 1985.PubMedGoogle Scholar
  60. 60.
    Yarchoan R, Brouwers P, Spitzer AR, et al: Response of HIV associated neurological disease to 3’Azido-3’-deoxythymidine. Lancet 1:132–135, 1987.Google Scholar
  61. 61.
    Price RW, Brew B, Sidtis J, et al: The brain in AIDS: Central nervous system HIV-1 infection and AIDS dementia complex. Science 239: 586–592, 1988.PubMedCrossRefGoogle Scholar
  62. 62.
    Solomon GF: Psychoneuroimmunology: Interactions between central nervous system and immune system. J Neurosci Res 18: 1–9, 1987.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • T. Peter Bridge
    • 1
  • Loring J. Ingraham
    • 1
  1. 1.Intramural Research ProgramNational Institute of Mental HealthBethesdaUSA

Personalised recommendations